Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIFED vs TENUATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Tenuate (diethylpropion) is a sympathomimetic amine that acts as an appetite suppressant. It stimulates the release of norepinephrine and to a lesser extent dopamine from presynaptic nerve terminals in the hypothalamus, increasing satiety.
Temporary relief of symptoms associated with allergic rhinitis (sneezing, rhinorrhea, pruritus),Temporary relief of nasal congestion due to common cold, hay fever, or other upper respiratory allergies
FDA-approved: short-term (up to 12 weeks) adjunct in a regimen of weight reduction based on caloric restriction in patients with exogenous obesity.,Off-label: long-term management of obesity (not FDA-approved for extended use).
1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.
25 mg orally three times daily before meals, or 75 mg extended-release orally once daily in the morning.
Triprolidine: 3.2 hours; Pseudoephedrine: 5–8 hours (p H-dependent: alkaline urine prolongs). Terminal half-life for clinical use typically 4–6 hours.
4-6 hours (terminal); clinical context: short half-life supports multiple daily dosing
Triprolidine: Hepatic metabolism via CYP450 enzymes. Pseudoephedrine: Partially metabolized in liver by N-demethylation; excreted unchanged in urine (70-90%).
Extensively metabolized in the liver via N-dealkylation to active metabolites (ethylaminopropiophenone and diethylaminopropiophenone). Enzymes involved include CYP3A4 and CYP2D6.
Renal: 80% (20% unchanged, 60% as metabolites). Fecal: 20% (unchanged and metabolites). Active tubular secretion of pseudoephedrine.
Renal (90% as metabolites, ~10% unchanged); minor biliary/fecal (<10%)
Triprolidine: 60% bound to serum albumin; Pseudoephedrine: 20–30% bound to plasma proteins (mainly albumin).
~92% (primarily albumin)
Triprolidine: 2.5–4.0 L/kg; Pseudoephedrine: 2.6–3.5 L/kg. Indicates extensive tissue distribution.
~4 L/kg (extensive tissue distribution, including CNS)
Oral: Triprolidine 90–100%; Pseudoephedrine 100% (first-pass metabolism negligible).
Oral: ~60-70% (first-pass metabolism)
Cr Cl 30-50 m L/min: extend dosing interval to every 8 hours. Cr Cl 15-29 m L/min: every 12 hours. Cr Cl <15 m L/min: not recommended.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation.
Child-Pugh A: no adjustment. Child-Pugh B: consider extending interval to every 8 hours. Child-Pugh C: avoid use.
Contraindicated in Child-Pugh Class C; use with caution in Class A and B, consider dose reduction.
Children 6-12 years: 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 6 hours; max 2 tablets/24 hours. Children <6 years: not recommended.
Not recommended for children under 16 years of age.
Start with 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 8 hours; monitor for CNS excitation and anticholinergic effects.
Initial dose at 12.5 mg twice daily; titrate slowly due to increased sensitivity and risk of adverse effects.
None.
There is no FDA boxed warning for Tenuate.
Cardiovascular effects: hypertension, palpitations, tachycardia, arrhythmias,CNS stimulation: nervousness, dizziness, insomnia, especially in elderly,May cause urinary retention in patients with prostatic hypertrophy,Use caution in patients with diabetes, hyperthyroidism, ischemic heart disease, increased intraocular pressure,Anticholinergic effects: dry mouth, blurred vision, constipation
Primary pulmonary hypertension: rare but serious condition associated with use.,Cardiac valvulopathy: risk increases with prolonged use or combination with other serotonergic drugs.,Tachyphylaxis: tolerance to anorectic effects may develop within a few weeks.,Psychiatric effects: may exacerbate psychiatric disorders, particularly in patients with history of substance abuse.,Seizures: risk increased in patients with epilepsy or history of seizures.
Hypersensitivity to triprolidine, pseudoephedrine, or any component,Severe hypertension or coronary artery disease,Monoamine oxidase inhibitor (MAOI) therapy (concurrent or within 14 days),Narrow-angle glaucoma,Urinary retention,During or within 14 days of MAOI use
Hypersensitivity to diethylpropion or other sympathomimetic amines.,Advanced arteriosclerosis, cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma.,History of drug abuse, agitated states.,Concurrent use (or within 14 days of discontinuing) MAO inhibitors (hypertensive crisis risk).
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) as pseudoephedrine may potentiate vasopressor effects. Grapefruit juice may decrease pseudoephedrine absorption; separate administration by at least 4 hours.
Avoid caffeine and other stimulants (e.g., in coffee, tea, cola, energy drinks) as they may increase cardiovascular side effects. Avoid high-tyramine foods (e.g., aged cheeses, cured meats, fermented products) if also taking MAOIs, but this is relevant only if transitioning therapy. No specific food restrictions otherwise, but a reduced-calorie diet is essential for efficacy.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk of premature labor, neonatal respiratory depression, and withdrawal symptoms with prolonged use. Use lowest effective dose for shortest duration.
First trimester: Limited human data, but animal studies suggest increased risk of cardiovascular and neural tube defects. Second and third trimesters: Associated with reduced fetal growth and neonatal withdrawal symptoms (tremors, hypertonia, feeding difficulties). Avoid use unless clearly needed.
Pseudoephedrine is excreted into breast milk; M/P ratio approximately 3.5. Triprolidine is present in milk. Potential for irritability, sleep disturbance in infants; may reduce milk supply. Use with caution; alternative preferred. Discontinue breastfeeding or drug based on necessity.
Excreted in human milk; M/P ratio not determined. Potential for adverse effects in nursing infants (e.g., irritability, poor weight gain). Use caution; decision to discontinue nursing or drug based on importance to mother.
No specific dose adjustment recommended for pregnancy; however, increased plasma volume may reduce drug concentrations. Use lowest effective dose due to limited safety data. Avoid in hypertension or preeclampsia.
No specific pharmacokinetic data; however, pregnancy may alter metabolism. Start with lowest effective dose (25 mg BID) and monitor clinical response. Avoid sustained-release formulations due to altered GI transit.
Actifed (pseudoephedrine + triprolidine) is contraindicated in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Pseudoephedrine can cause CNS stimulation and insomnia, so avoid evening dosing. Triprolidine is a first-generation antihistamine with significant anticholinergic effects; use caution in elderly or those with BPH, urinary retention, or asthma.
Tenuate (diethylpropion) is a sympathomimetic amine anorectic indicated for short-term (8-12 weeks) adjunct in obesity management. Avoid in patients with history of drug abuse, cardiovascular disease, hyperthyroidism, or glaucoma. Monitor blood pressure and heart rate regularly. Tolerance may develop; discontinue if tolerance occurs. Contraindicated with MAOIs or within 14 days of their use. May impair ability to drive or operate machinery.
Do not take with other cold or allergy medications containing decongestants or antihistamines.,Avoid alcohol and sedatives as they may increase drowsiness.,Do not crush or chew extended-release tablets; swallow whole.,Monitor for increased blood pressure or heart rate; discontinue if palpitations occur.,May cause dizziness; avoid driving or operating heavy machinery until you know how it affects you.
Take exactly as prescribed; do not increase dose or duration.,May cause dizziness or blurred vision; avoid driving if affected.,Inform your doctor if you have heart disease, high blood pressure, or thyroid problems.,Avoid alcohol and other CNS stimulants while taking this medication.,Report any chest pain, palpitations, or severe headache immediately.,Do not take with other appetite suppressants without consulting your doctor.,This medication is only for short-term use; combine with diet and exercise.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIFED vs TENUATE, answered by our medical review team.
ACTIFED is a Decongestant/Antihistamine Combination that works by ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. TENUATE is a Sympathomimetic anorectic that works by Tenuate (diethylpropion) is a sympathomimetic amine that acts as an appetite suppressant. It stimulates the release of norepinephrine and to a lesser extent dopamine from presynaptic nerve terminals in the hypothalamus, increasing satiety.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIFED and TENUATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIFED is: 1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.. The standard adult dose of TENUATE is: 25 mg orally three times daily before meals, or 75 mg extended-release orally once daily in the morning.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIFED and TENUATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIFED is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk . TENUATE is classified as Category C. First trimester: Limited human data, but animal studies suggest increased risk of cardiovascular and neural tube defects. Second and third trimesters: Associated with reduced fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.